Crohn's Disease and Colitis Trial, Recruiting NCT06006039 Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT06006039
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older.
  • You must be male, or a female who is not currently pregnant or breastfeeding.
  • You must have had bowel surgery and then shown signs of Crohn's disease coming back, confirmed by a camera test (endoscopy) done 6 to 24 months after surgery, showing ulcers in the area where your bowel was reconnected.
  • In the doctor's opinion, you are able to understand and follow the study requirements.
  • You must be willing to sign a consent form agreeing to take part before any study activities begin.

Who may not be able to join:

  • You have conditions such as a history of alcohol or substance misuse, or difficulty following medical instructions, that the doctor believes could affect your ability to take part properly.
  • You have a health condition that would make one of the possible treatments unsafe for you — for example, severe heart failure, multiple sclerosis, or an active infection (confirm with trial site).
  • You have taken part in another clinical trial involving an experimental drug in the last 30 days or longer (confirm with trial site).
  • You are currently in, or planning to join, another study involving an experimental treatment.
  • You are pregnant, planning to become pregnant, or plan to become pregnant during the study.
  • You have previously been diagnosed with pre-cancerous changes (dysplasia) in the colon, unless it was only found in a removed polyp.
  • You have had a cancer diagnosis in the 3 years before joining the study, except for a common type of skin cancer (non-melanoma skin cancer).
  • You received a biologic therapy (a type of advanced medication) between your surgery and your first camera test after surgery.
  • You currently have a gut infection caused by a bacteria called Clostridium difficile — although if you test positive, you may still be able to join if you are successfully treated and test negative within 4 weeks of your screening visit.
  • You have a stoma bag and your bowel has not been reconnected internally.
  • You have an active abscess or open, draining fistula in the area around your bottom.
  • Your liver enzyme levels (ALT or AST) are more than 3 times the normal upper limit based on blood tests at screening.
  • You have a condition that increases your risk of bleeding, such as a blood clotting disorder, or you are taking blood-thinning medications.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 020 444 1125

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Registry
ClinicalTrials.gov
Start date
5 June 2023
Est. completion
1 January 2027

Where this trial is recruiting

🇨🇦 Canada 🇳🇱 Netherlands

Primary endpoints

Changes in concentration and amounts of IL-23 responsive cells in postoperative CD at baseline endoscopy and after 12-16 weeks of routine care treatment with a biological agent.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov